Clinical efficacy of emittenofovir tablets combined with peginterferon α-2b in the treatment of chronic viral hepatitis B
FU Xiling
ZHU Mengying
JIAO Damin
MA Yuqi
LU Naiying
CHANG Jiabao
Abstract：Objective To explore the clinical efficacy of amitinofovir tablets combined with peg-interferon α-2b in the treatment of chronic viral hepatitis B.Methods A retrospective analysis was conducted on 110 patients with chronic viral hepatitis B treated in our hospital from August 2021 to June 2023.According to the different treatment regiments,the patients were divided into the amitinofovir group(56 cases)and the combination therapy group(54 cases).The amitinofovir group was given oral amitinofovir tablets treatment,25 mg each time,once a day.In the combination treatment group,polyethylene glycol interferon α-2b injection was added to the treatment of the Amitinofovir group.The clinical efficacy of these 2 groups was compared with the treatment after 24/48 weeks of treatment.Results After 24 weeks of treatment,there was no significant difference in hepatitis B e antigen(HBeAg)conversion rate,hepatitis B surface antigen(HBsAg)clearance rate and HBV DNA conversion rate between the combination treatment group and the emitenofovir group(P＞0.05).After 48 weeks of treatment,the HBeAg conversion rate and HBsAg clearance rate of patients in the combination treatment group were 38.9%and 22.2%,which were significantly better than those in the emitenofovir group(16.1%and 1.8%,P＜0.05),and the HBV DNA conversion rates in the combination treatment group and the emitenofovir group were 98.1%and 92.9%,respectively,with no significant difference(P＞0.05).After 24 weeks of treatment,there was no significant difference in total bilirubin(TBIL)level,alanine aminotransferase(ALT)level,aspartate aminotransferase(AST)level and gamma-glutamyl transpeptidase(GGT)level between the combination treatment group and the emitenofovir group(P＞0.05).After 48 weeks of treatment,the levels of TBIL,ALT,AST and GGT in patients with chronic viral hepatitis B in the combination treatment group were significantly higher than those in the emitenofovir group(P＜0.01).The adverse reactions of the emitenofovir group in the treatment of chronic viral hepatitis B were 14.3%,which was significantly lower than that in the combination group(96.3%)(P＜0.00).Conclusions The clinical efficacy of amitinofovir tablets combined with peg-interferon α-2b in the treatment of chronic viral hepatitis B is significantly better than that of amitinofovir tablets alone,but the incidence of adverse reactions is higher.
Keywords：amitinofovirpeg-interferon α-2bchronic viral hepatitis Bcombination therapyclinical efficacy
Publication Date：2023-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 509-511,526 )